Metabolism of 17-phenyl-18,19,20-trinor-prostaglandin F 2α in the cynomolgus monkey and the human female

Abstract

[9β- 3H]-17-Phenyl-18,19,20-trinor-PGF 2α was injected subcutaneously into female Cynomolgus monkeys and the structures of six products appearing in the urine were determined. The main urinary metabolites were the dinor- and tetranor-derivatives of 15-keto-13,14-dihydro-17-phenyl-18,19,20-trinor-PGF 2α. Unchanged 17-phenyl-18,19,20-trinor-PGF 2α was also identified among the urinary products, as well as its dinor- and tetranor-derivatives. Finally, the dinor-derivative of 13,14-dihydro-17-phenyl-18,19,20-trinor-PGF 2α was also found in urine. The same six products were also found in urine from human female subjects that had received 17-phenyl-18,19,20-trinor-PGF 2α either subcutaneously or intravenously. Studies on the half-life of the compound in the circulation were also performed in human females. Two less polar metabolites in plasma were identified, viz. 13,14-dihydro-17-phenyl-18,19,20-trinor-PGF 2α and 15-keto-13,14-dihydro-17-phenyl-18,19,20-trinor-PGF 2α.